Coming October 30: SABCS releases its session titles, and the full abstracts follow on November 23. We’ll add the program and the organizations presenting it once they’re out.

Hormone receptor-positive breast cancer at SABCS 2026

Dec 8–11, 2026 San Antonio, TX ~11k attendees Website

17 organizations at SABCS 2026 present work in hormone receptor-positive breast cancer: 14 drug developers and 3 diagnostics, device and service companies. 17 of them have their own page in this guide. As of Sep 27, 2026.

All 124 organizations at SABCS 2026 →

Showing 1–17 of 17 organizations

Organization	SABCS 2026 Attendance
AstraZeneca Cambridge, UK
astrazeneca.com Pharma Global drugmaker whose breast cancer medicines include HER2- and TROP2-directed antibody-drug conjugates and treatments for hormone receptor-positive disease.	Booth Exhibiting at Booth 624 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
BeOne Medicines Basel, Switzerland
beonemedicines.com Pharma Global oncology company developing and selling treatments for blood cancers and solid tumors, aiming for wider and more affordable access.	Booth Exhibiting at Booth 1543 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Celcuity Minneapolis, MN
celcuity.com Biotech Clinical-stage company developing gedatolisib, a PI3K/mTOR pathway inhibitor, for HR+/HER2- advanced breast cancer.	Booth Exhibiting at Booth 1510 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Pharma Japanese drugmaker whose oncology portfolio centers on antibody-drug conjugates, including HER2- and TROP2-directed treatments used in breast cancer.	Booth Exhibiting at Booth 343 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Delphi Diagnostics Houston, TX
delphi-diagnostics.com Diagnostics Commercializing a test licensed from MD Anderson that scores endocrine activity in HR+/HER2- stage II–III tumors to guide therapy.	Booth Exhibiting at Booth 1528 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Eli Lilly and Company Indianapolis, IN
lilly.com Pharma Global drugmaker whose cancer medicines include treatments for hormone receptor-positive breast cancer.	Booth Exhibiting at Booth 324 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Exact Sciences Madison, WI
exactsciences.com Diagnostics Cancer screening and diagnostics company, now part of Abbott, known for the Oncotype DX breast recurrence test and the Cologuard screening test.	Booth Exhibiting at Booth 843 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Genentech South San Francisco, CA
gene.com Pharma Roche Group biotechnology company whose breast cancer medicines include HER2-targeted antibodies and treatments for hormone receptor-positive disease.	Booth Exhibiting at Booth 125 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Gilead Sciences Foster City, CA
gilead.com Pharma Biopharma company whose cancer portfolio spans antibody-drug conjugates, small molecules and, through Kite, cell therapies.	Booth Exhibiting at Booth 608 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Hologic Marlborough, MA
hologic.com Diagnostics Women's health technology company whose Breast Cancer Index test helps decide whether early HR+ breast cancer warrants hormone therapy beyond five years.	Booth Exhibiting at Booth 915 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Menarini-Stemline New York, NY
stemline.com Pharma Oncology company in the Menarini Group that markets elacestrant (Orserdu) for ESR1-mutated, ER+/HER2- advanced breast cancer.	Booth Exhibiting at Booth 309 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Novartis Basel, Switzerland
novartis.com Pharma Swiss drugmaker whose breast cancer medicines include treatments for hormone receptor-positive disease.	Booth Exhibiting at Booth 643, 1142 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Olema Oncology San Francisco, CA
olema.com Biotech Clinical-stage company developing palazestrant, an oral estrogen receptor antagonist and degrader, in Phase 3 trials for ER+/HER2- advanced breast cancer.	Booth Exhibiting at Booth 1342 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Pfizer New York, NY
pfizer.com Pharma Global drugmaker whose breast cancer medicines include treatments for hormone receptor-positive and HER2-positive disease.	Booth Exhibiting at Booth 1124 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Puma Biotechnology Los Angeles, CA
pumabiotechnology.com Biotech Markets NERLYNX (neratinib) for HER2-positive breast cancer and is testing alisertib with hormone therapy in HR+/HER2- metastatic breast cancer.	Booth Exhibiting at Booth 209 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
Relay Therapeutics Cambridge, MA
relaytx.com Biotech Clinical-stage company combining computation and experiments to design small-molecule drugs, including a PI3Kα inhibitor for HR+/HER2- breast cancer.	Booth Exhibiting at Booth 1450 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm
TerSera Therapeutics Deerfield, IL
tersera.com Biotech Specialty biopharma company with oncology and rare-disease medicines, including goserelin (Zoladex) in the US.	Booth Exhibiting at Booth 808 Wed, Dec 912:00pm–6:30pmThu, Dec 1012:00pm–6:30pmFri, Dec 1112:00pm–3:00pm

Instantly find 20 buyers in hormone receptor-positive breast cancer

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Browse SABCS 2026 by

Organization type

Focus

Exhibit hall

Exhibitors 124

Everyone

All organizations A–Z 124

Not affiliated with the San Antonio Breast Cancer Symposium, UT Health San Antonio or the American Association for Cancer Research. Organization details are derived from SABCS’s published exhibitor list. Submit a correction